Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

ClinicalTrials.gov ID: NCT05984199

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05984199. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).

Study identification

NCT ID: NCT05984199
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Vor Biopharma; Industry
Enrollment: 38 participants

Conditions and interventions

Conditions

Leukemia, Myeloid, Acute

Interventions

VCAR33 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 11, 2023 (Actual)
Primary completion: May 28, 2025 (Actual)
Completion: May 28, 2025 (Actual)
Last update posted: Jul 29, 2025

2023 – 2025

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of California San Diego Moores Cancer Center	La Jolla	California	92093	—
Stanford Cancer Institute	Stanford	California	94305	—
Miami Cancer Institute	Miami	Florida	33176	—
Winship Cancer Institute Emory University	Atlanta	Georgia	30322	—
The University of Kansas Cancer Center	Fairway	Kansas	66205	—
National Institutes of Health, Clinical Center	Bethesda	Maryland	20892	—
University of Michigan Health	Ann Arbor	Michigan	48109	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota	55455	—
Washington University School of Medicine Siteman Cancer Center	St Louis	Missouri	63110	—
John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Icahn School of Medicine at Mount Sinai	New York	New York	10029	—
University Hospitals Seidman Cancer Center	Cleveland	Ohio	44106	—
University of Utah Huntsman Cancer Institute	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05984199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 29, 2025 · Synced Nov 14, 2026